FDA Migraine Guidance Offers ‘Alternative’ Trial Design With Patient-Focused Endpoint
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Sponsor would need “no pain” result at two hours, but could use patient-identified symptom as co-primary endpoint.
You may also be interested in...
Migraine Snapshot: Despite Significant Generic Presence, MAP, Allergan, Others See Big Market Potential
After a 20-year hiatus, the market for acute and chronic migraine is set to expand with the introduction of Allergan’s Botox and of novel formulations of triptans and alternative therapies.
Rare Disease Roundtable: Dealing With Pricing Pressure
Part 2: High costs are built into the rare disease business model. Participants at a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference talked about how much they are feeling the pressure on pricing.
Rare Disease Roundtable: How Rare Is Too Rare?
Part 1: Execs from rare disease-focused companies weighed in on investor sentiment during a roundtable discussion led by Scrip at the J.P. Morgan Healthcare Conference.